Japan: Results & Revisions Update - Slowing Momentum Confirmed
DOUBLE-DIGIT YOY GROWTH BUT RISING COSTSÂ A CONCERN- 27% of Japanese listed companies reported earnings results last week. In aggregate, the group...
440 Views
Opdivo Potential Capped Due to Pricing Pressure and Keytruda Competition
We reiterate our âEqual-weightâ rating on the stock after reviewing our model post FY17 (YE Mar-18) earningsKey HighlightsBrisk Opdivo royalty...
508 Views
Merck Alliance Provides Stability to Deal With the Outcome of High Risk Alzheimerâs R&D in FY19
We upgrade Eisai Co Ltd (4523 JP)Â to âEqual-weightâ after reviewing our model post FY17 (YE Mar-18) earnings, in light of the augmented peak sales...
341 Views
Opportunities in The (Overpriced) Japan Pharma Sector
As a defensive sector, Japanâs pharmaceutical sector has had an up-and-down time of it during the Abe era. In the early days of Abenomics, the...
237 Views
Ono FY17 Earnings - First Glance
Ono Pharmaceutical Co Ltd (4528 JP) reported FY17 results on May 10, 2018 Opdivo led FY17 topline growth and gross margins expansion in line with...
184 Views